{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:40:28Z","timestamp":1786711228030,"version":"build-2736575974"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG 2021 - ID. 26011 to RC"],"award-info":[{"award-number":["IG 2021 - ID. 26011 to RC"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:title>Editorial on the research topic<\/jats:title>\n                  <jats:p>Next-Generation Treatment for Pediatric Cancer: Advancing Immunotherapy through Combinations. Cancer remains one of the leading causes of disease-related mortality among children and adolescents. Despite advances in treatments, outcomes for many pediatric tumors remain limited, particularly in patients with high-risk, relapsed, or refractory disease. Standard therapies, including surgery, chemotherapy, radiotherapy, and stem cell transplantation, are frequently associated with severe long-term toxicities and secondary malignancies. Resistance and relapse remain major clinical challenges. Recent progress in cancer immunotherapy has revolutionized adult oncology, and remarkable clinical advances have been observed in several pediatric cancers. However, comparable benefits in most solid tumors remain limited. Among molecular targets, anaplastic lymphoma kinase (ALK) has emerged as a critical driver of tumorigenesis in several pediatric malignancies, including anaplastic large cell lymphoma (ALCL), neuroblastoma and inflammatory myofibroblastic tumor. While ALK tyrosine kinase inhibitors have demonstrated clinical benefit, the emergence of resistance highlights the need for alternative or complementary strategies. ALK can act as an oncoantigen, as shown by spontaneous ALK-specific humoral and T-cell responses in patients with ALK-positive ALCL, and ALK-directed immunotherapies have been developed and have shown efficacy in preclinical models of ALK-positive tumors, including ALCL and neuroblastoma. Therefore, ALK-directed immunotherapies represent biologically rational and promising approaches that may, if proven safe and effective in clinical trials, address resistance and improve long-term disease control. In this review, we will discuss ALK-specific immunotherapies, including ALK vaccines, ALK CAR-T and other cellular therapies, as well as ALK-targeting antibodies with a particular focus on pediatric ALK-positive tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1912199","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:14:36Z","timestamp":1786709676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Monica","family":"Maccagno","sequence":"first","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Tagliero","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Chiarle","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino","place":["Torino, Italy"]},{"name":"Department of Hematopathology, IEO European Institute of Oncology IRCCS","place":["Milan, Italy"]},{"name":"Department of Pathology, Children\u2019s Hospital and Harvard Medical School, Boston","place":["MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Voena","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1094","article-title":"A summary of the inaugural WHO classification of pediatric tumors: Transitioning from the optical into the molecular era","volume":"12","author":"Pfister","year":"2022","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063225","article-title":"Pediatric solid cancers: Dissecting the tumor microenvironment to improve the results of clinical immunotherapy","volume":"25","author":"Belgiovine","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1100","article-title":"Anaplastic lymphoma kinase as a cancer target in pediatric Malignancies","volume":"22","author":"Moss\u00e9","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201062","article-title":"ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin\u2019s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)","volume":"14","author":"Morris","year":"1997","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: From function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13333","article-title":"The role of anaplastic lymphoma kinase in pediatric cancers","volume":"108","author":"Takita","year":"2017","journal-title":"Cancer Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108731","article-title":"CD30 expression and its functions during the disease progression of adult T-cell leukemia\/lymphoma","volume":"24","author":"Nakashima","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5858\/2001-125-1036-CEIFL","article-title":"CD30 expression in follicular lymphoma","volume":"125","author":"Gardner","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05808.x","article-title":"Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation*","volume":"131","author":"Perkins","year":"2005","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204735","article-title":"The proteomic signature of NPM\/ALK reveals deregulation of multiple cellular pathways","volume":"114","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5411","article-title":"Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: Results of the ALCL99 study","volume":"29","author":"Lamant","year":"2011","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2019.1558399","article-title":"Brentuximab vedotin in T-cell lymphoma","volume":"12","author":"Van Der Weyden","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13344","article-title":"Brentuximab vedotin exerts profound antiproliferative and pro\u2010apoptotic efficacy in CD30\u2010positive as well as cocultured CD30\u2010negative germ cell tumour cell lines","volume":"22","author":"Sch\u00f6nberger","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30+ lymphoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children\u2019s Oncology Group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase\u2010positive anaplastic large cell lymphoma: An open\u2010label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive Malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1182\/blood-2024-200077","article-title":"Brigatinib monotherapy in children with R\/R ALK+ ALCL, IMT, or other solid tumors: Updated results from the Brigaped (ITCC-098) phase 1 dose-escalation study","volume":"144","author":"Rigaud","year":"2024","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.hoc.2009.11.011","article-title":"Neuroblastoma: Biology, prognosis, and treatment","volume":"24","author":"Park","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030751","article-title":"Expression of immunomodulatory checkpoint molecules in drug-resistant neuroblastoma: An exploratory study","volume":"14","author":"Skertich","year":"2022","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Moss\u00e9","year":"2008","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ng1130","article-title":"Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome","volume":"33","author":"Amiel","year":"2003","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1086\/383253","article-title":"Germline mutations of the paired\u2013like homeobox 2B (PHOX2B) gene in neuroblastoma","volume":"74","author":"Trochet","year":"2004","journal-title":"Am J Hum Genet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/children6010005","article-title":"Non-high-risk neuroblastoma: Classification and achievements in therapy","volume":"6","author":"Meany","year":"2019","journal-title":"Children"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235897","article-title":"Chromosome imbalances in neuroblastoma\u2014recent molecular insight into chromosome 1p-deletion, 2p-gain, and 11q-deletion identifies new friends and foes for the future","volume":"13","author":"Guan","year":"2021","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.6719137","article-title":"Amplification of N- myc in untreated human neuroblastomas correlates with advanced disease stage","volume":"224","author":"Brodeur","year":"1984","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198510313131802","article-title":"Association of multiple copies of the N- myc oncogene with rapid progression of neuroblastomas","volume":"313","author":"Seeger","year":"1985","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy022","article-title":"Genomic amplifications and distal 6q loss: Novel markers for poor survival in high-risk neuroblastoma patients","volume":"110","author":"Depuydt","year":"2018","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3333","article-title":"Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations","volume":"47","author":"Eleveld","year":"2015","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00086","article-title":"Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)","volume":"39","author":"Bellini","year":"2021","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/PO.20.00181","article-title":"Differential impact of ALK mutations in neuroblastoma","volume":"5","author":"O\u2019Donohue","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25043","article-title":"Long\u2010term effects of crizotinib in ALK\u2010positive tumors (excluding NSCLC): A phase 1b open\u2010label study","volume":"93","author":"Gambacorti\u2010Passerini","year":"2018","journal-title":"Am J Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02297-5","article-title":"Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results","volume":"29","author":"Goldsmith","year":"2023","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.24.4077","article-title":"Phase I study of chimeric human\/murine anti\u2013ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children\u2019s Cancer Group study","volume":"18","author":"Ozkaynak","year":"2000","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17081327","article-title":"Inflammatory myofibroblastic tumor: An updated review","volume":"17","author":"Choi","year":"2025","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5114\/kitp.2025.148514","article-title":"Inflammatory myofibroblastic tumor of the lung: a comprehensive narrative review of clinical and therapeutic insights","volume":"22","author":"Leivaditis","year":"2025","journal-title":"Pol J Cardiothorac Surg"},{"key":"B48","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/pbc.20294","article-title":"Pediatric inflammatory myofibroblastic tumor: Anaplastic lymphoma kinase (ALK) expression and prognosis","volume":"45","author":"Chun","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00383","article-title":"Impact of ALK inhibitors in patients with ALK -rearranged nonlung solid tumors","volume":"5","author":"Takeyasu","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.761558","article-title":"Durable clinical response to ALK tyrosine kinase inhibitors in epithelioid inflammatory myofibroblastic sarcoma harboring PRRC2B-ALK rearrangement: A case report","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B51","volume-title":"Soft Tissue and Bone Tumours","year":"2020"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092028","article-title":"Pediatric rhabdomyosarcoma: Epidemiology and genetic susceptibility","volume":"10","author":"Martin-Giacalone","year":"2021","journal-title":"J Clin Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5211","article-title":"Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001\u20132017","volume":"12","author":"McEvoy","year":"2023","journal-title":"Cancer Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3814","article-title":"Fusion gene\u2013negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma","volume":"28","author":"Williamson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.137","article-title":"PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children\u2019s oncology group","volume":"20","author":"Sorensen","year":"2002","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5591","article-title":"PAX3\/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification","volume":"30","author":"Missiaglia","year":"2012","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2018.08.017","article-title":"Treatment approach and outcomes in infants with localized rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children\u2019s oncology group","volume":"103","author":"Bradley","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.653","article-title":"High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma","volume":"109","author":"Bonvini","year":"2013","journal-title":"Br J Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1297","article-title":"PAX3\u2013FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability","volume":"7","author":"Gryder","year":"2017","journal-title":"Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132330","article-title":"Understanding the interplay between expression, mutation and activity of ALK receptor in rhabdomyosarcoma cells for clinical application of small-molecule inhibitors","volume":"10","author":"Peron","year":"2015","journal-title":"PloS One"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3615-7","article-title":"Targeting ALK in pediatric RMS does not induce antitumor activity in vivo","volume":"82","author":"Wierdl","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.011","article-title":"The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 \u2018CREATE\u2019","volume":"94","author":"Sch\u00f6ffski","year":"2018","journal-title":"Eur J Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31148","article-title":"Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC\u2013ALK gene fusion","volume":"71","author":"Akane","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100703","article-title":"Expression of anaplastic lymphoma kinase (ALK) in glioma and possible clinical correlations. A retrospective institutional study","volume":"36","author":"Azab","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3521","article-title":"ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma","volume":"29","author":"Blandin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102393","article-title":"Safety and efficacy of crizotinib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib GEINO 1402 trial","volume":"14","author":"Mart\u00ednez-Garc\u00eda","year":"2022","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1268038","article-title":"Pediatric CNS tumors and 2021 WHO classification: What do oncologists need from pathologists","volume":"17","author":"d\u2019Amati","year":"2024","journal-title":"Front Mol Neurosci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101264","article-title":"Lorlatinib in a child with ALK -fusion\u2013positive high-grade glioma","volume":"385","author":"Bagchi","year":"2021","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28355","article-title":"Ewing sarcoma","volume":"68","author":"Eaton","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/pin.13293","article-title":"Ewing and Ewing\u2010like sarcomas: A morphological guide through genetically\u2010defined entities","volume":"73","author":"Yoshida","year":"2023","journal-title":"Pathol Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28047","article-title":"Expression and clinical relevance of MET and ALK in Ewing sarcomas","volume":"133","author":"Fleuren","year":"2013","journal-title":"Int J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12885-025-14130-y","article-title":"Tyrosine kinase inhibitors in Ewing\u2019s sarcoma: A systematic review","volume":"25","author":"Assi","year":"2025","journal-title":"BMC Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030465","article-title":"Multi-targeted TKIs in patients with advanced Ewing sarcoma: A systematic review and single-arm meta-analysis","volume":"18","author":"Michelon","year":"2026","journal-title":"Cancers"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023717","article-title":"Renal cell carcinoma in children and adolescents: Single-center experience and literature review","volume":"100","author":"He","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2016.07.004","article-title":"TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation","volume":"212","author":"Thorner","year":"2016","journal-title":"Pathol Res Pract"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000761","article-title":"A comparison of morphologic and molecular features of BRAF, ALK, and NTRK1 fusion spitzoid neoplasms","volume":"41","author":"Amin","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2784-8","article-title":"The ALK receptor in sympathetic neuron development and neuroblastoma","volume":"372","author":"Janoueix-Lerosey","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1605","article-title":"Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma","volume":"96","author":"Pulford","year":"2000","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040114","article-title":"Immune response against ALK in children with ALK-positive anaplastic large cell lymphoma","volume":"10","author":"Stadler","year":"2018","journal-title":"Cancers"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251892","article-title":"Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase\u2013positive anaplastic large cell lymphoma with tumor dissemination and relapse risk","volume":"115","author":"Ait-Tahar","year":"2010","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0445","article-title":"Endogenous CD4+ T cells that recognize ALK and the NPM1::ALK fusion protein can be expanded from human peripheral blood","volume":"13","author":"Stadler","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B84","first-page":"48","article-title":"In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas","volume":"91","author":"Passoni","year":"2006","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1625688","article-title":"NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma","volume":"8","author":"Singh","year":"2019","journal-title":"OncoImmunology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm1769","article-title":"The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination","volume":"14","author":"Chiarle","year":"2008","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0089","article-title":"Efficacy of a cancer vaccine against ALK -rearranged lung tumors","volume":"3","author":"Voena","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00591-2","article-title":"ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer","volume":"4","author":"Mota","year":"2023","journal-title":"Nat Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1158\/1538-7445.AM2026-6716","article-title":"Abstract 6716: ALK-mRNA vaccine as a new immunotherapy for ALK+ cancers","volume":"86","author":"Saccu","year":"2026","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501972200","article-title":"Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin","volume":"280","author":"Moog-Lutz","year":"2005","journal-title":"J Biol Chem"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.647","article-title":"Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma","volume":"31","author":"Carpenter","year":"2012","journal-title":"Oncogene"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9732","article-title":"An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma","volume":"11","author":"Sano","year":"2019","journal-title":"Sci Transl Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"7578","DOI":"10.1038\/s41467-025-62979-1","article-title":"A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers","volume":"16","author":"Guerra","year":"2025","journal-title":"Nat Commun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04141-7","article-title":"Structural basis for ligand reception by anaplastic lymphoma kinase","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03959-5","article-title":"Structural basis of cytokine-mediated activation of ALK family receptors","volume":"600","author":"De Munck","year":"2021","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040065","article-title":"Discovery strategies to maximize the clinical potential of T-cell engaging antibodies for the treatment of solid tumors","volume":"9","author":"Voynov","year":"2020","journal-title":"Antibodies"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20251652","article-title":"T cell engagers emerge as a compelling therapeutic modality","volume":"223","author":"Baeuerle","year":"2026","journal-title":"J Exp Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/antib13020039","article-title":"Identification of a fully human antibody VH domain targeting anaplastic lymphoma kinase (ALK) with applications in ALK-positive solid tumor immunotherapy","volume":"13","author":"Chen","year":"2024","journal-title":"Antibodies"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","article-title":"ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells","volume":"41","author":"Bergaggio","year":"2023","journal-title":"Cancer Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65042-0","article-title":"Expression of the ALK tyrosine kinase gene in neuroblastoma","volume":"156","author":"Lamant","year":"2000","journal-title":"Am J Pathol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4419","article-title":"Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients","volume":"69","author":"Passoni","year":"2009","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-022-00517-5","article-title":"ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma","volume":"18","author":"Somasundaram","year":"2022","journal-title":"World J Pediatr"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.595","article-title":"The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking","volume":"30","author":"Mazot","year":"2011","journal-title":"Oncogene"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1538-7445.AM2024-21","article-title":"Abstract 21: Discovery of ALK-specific TCR clonotypes for the development of TCR-T cell therapies against ALK-positive cancers","volume":"84","author":"Mecca","year":"2024","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1182\/blood-2025-5909","article-title":"Development of ALK-directed TCR-T cells with potent and specific anti-tumor activity against ALK-positive anaplastic large cell lymphoma","volume":"146","author":"Piane","year":"2025","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1538-7445.AM2026-5619","article-title":"Abstract 5619: First-in-class anaplastic lymphoma kinase (ALK)-specific TCR-T cells induce potent and selective antitumor immunity across ALK-driven human cancers","volume":"86","author":"Mecca","year":"2026","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: An overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00823-2","article-title":"FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma","volume":"31","author":"Xiao","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12181","article-title":"4SCAR\u2010GD2\u2010modified T\u2010cell therapy in neuroblastoma with MYCN amplification: A case report with over 4\u2010year follow\u2010up data","volume":"4","author":"Xu","year":"2020","journal-title":"Pediatr Investig"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162865","article-title":"Current knowledge and perspectives of immunotherapies for neuroblastoma","volume":"16","author":"Mao","year":"2024","journal-title":"Cancers"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115263","article-title":"Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma","volume":"218","author":"Strijker","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1912199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:14:37Z","timestamp":1786709677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1912199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":114,"alternative-id":["10.3389\/fimmu.2026.1912199"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1912199","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1912199"}}